Body mass index is weakly associated with, and not a helpful predictor of, disease progression in men with clinically localized prostate carcinoma treated with radical prostatectomy

Cancer

Volumn 103, Issue 10, 2005, Pages 2030-2034

  Mallah, Kozhaya N ^a   DiBlasio, Christopher J ^a   Rhee, Audrey C ^a   Scardino, Peter T ^a   Kattan, Michael W ^a,b  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Body mass index; Disease progression; Obesity; Prostate carcinoma; Reciprocal of body mass index

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

AREA UNDER THE CURVE; ARTICLE; BODY FAT; BODY MASS; CALCULATION; CANCER GRADING; CANCER GROWTH; CANCER MORTALITY; CANCER RISK; CLINICAL FEATURE; CORRELATION ANALYSIS; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; OBESITY; PREDICTION; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROBABILITY; PROGNOSIS; PROSTATE CARCINOMA; PROSTATECTOMY; RACE; RADICAL RETROPUBIC PROSTATECTOMY; RETROSPECTIVE STUDY; RISK FACTOR; TUMOR BIOPSY; UNITED STATES;

AREA UNDER CURVE; BIOPSY; BODY MASS INDEX; CARCINOMA; COHORT STUDIES; CONTINENTAL POPULATION GROUPS; DISEASE PROGRESSION; FOLLOW-UP STUDIES; FORECASTING; HUMANS; MALE; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; OBESITY; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; ROC CURVE;

EID: 18044375156     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.20991     Document Type: Article

References (26)

1. Flegal KM, Carroll MD, Ogden CL, Johnson CL. Prevalence and trends in obesity among US adults, 1999-2000. JAMA. 2002;288:1723-1727.
2. Frisancho AR. Anthropometric standards for the assessment of growth and nutritional status. Ann Arbor: University of Michigan Press, 1990.
3. Flegal KM. Anthropometric evaluation of obesity in epidemiologic research on risk factors: blood pressure and obesity in the health examination survey. PhD dissertation (UMI:8228449), Cornell University, 1982.
4. Flegal KM. Is an inverted weight-height index a better index of body fatness [abstract]? Obes Res. 1997;5:93S.
5. Fernandez JR, Heo M, Heymsfield SB, et al. Is percentage body fat differentially related to body mass index in Hispanic Americans, African Americans, and European Americans? Am J Clin Nutr. 2003;77:71-75.
6. Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med. 2003;348:1625-1638.
7. Jonsson F, Wolk A, Pedersen NL, et al. Obesity and hormone-dependent tumors: cohort and co-twin control studies based on the Swedish Twin Registry. Int J Cancer. 2003;106:594-599.
8. Jemal A, Tiwari RC, Murray T, et al. Cancer statistics, 2004. CA Cancer J Clin. 2004;54:8-29.
9. Mydlo JH, Tieng NL, Volpe MA, Chaiken R, Kral JG. A pilot study analyzing PSA, serum testosterone, lipid profile, body mass index and race in a small sample of patients with and without carcinoma of the prostate. Prostate Cancer Prostatic Dis. 2001;4:101-105.
10. Hsing AW, Deng J, Sesterhenn IA, et al. Body size and prostate cancer: a population-based case-control study in China. Cancer Epidemiol Biomarkers Prev. 2000;9:1335-1341.
11. Schuurman AG, Goldbohm RA, Dorant E, van den Brandt PA. Anthropometry in relation to prostate cancer risk in the Netherlands Cohort Study. Am J Epidemiol. 2000;151:541-549.
12. Irani J, Lefebvre O, Murat F, Dahmani L, Dore B. Obesity in relation to prostate cancer risk: comparison with a population having benign prostatic hyperplasia. BJU Int. 2003;91:482-484.
13. Amling CL, Kane CJ, Riffenburgh RH, et al. Relationship between obesity and race in predicting adverse pathologic variables in patients undergoing radical prostatectomy. Urology. 2001;58:723-728.
14. Amling CL, Riffenburgh RH, Sun L, et al. Pathologic variables and recurrence rates as related to obesity and race in men with prostate cancer undergoing radical prostatectomy. J Clin Oncol. 2004;22:439-445.
15. Chang S, Hursting SD, Contois JH, et al. Leptin and prostate cancer. Prostate. 2001;46:62-67.
16. Freedland SJ, Aronson WJ, Kane CJ, et al. Impact of obesity on biochemical control after radical prostatectomy for clinically localized prostate cancer: a report by the Shared Equal Access Regional Cancer Hospital database study group. J Clin Oncol. 2004;22:446-453.
17. Yan Y, Carvalhal GF, Catalona WJ, Young JD. Primary treatment choices for men with clinically localized prostate carcinoma detected by screening. Cancer. 2000;88:1122-1130.
18. Chen Z, Maricic M, Nguyen P, Ahmann FR, Bruhn R, Dalkin BL. Low bone density and high percentage of body fat among men who were treated with androgen deprivation therapy for prostate carcinoma. Cancer. 2002;95:2136-2144.
19. Physical status: the use and interpretation of anthropometry. Report of a WHO Expert Committee. World Health Organ Tech Rep Ser. 1995;854:1-452.
20. Andersson SO, Wolk A, Bergstrom R, et al. Body size and prostate cancer: a 20-year follow-up study among 135006 Swedish construction workers. J Natl Cancer Inst. 1997;89:385-389.
21. Moller H, Mellemgaard A, Lindvig K, Olsen JH. Obesity and cancer risk: a Danish record-linkage study. Eur J Cancer. 1994;30A:344-350.
22. Rohrmann S, Roberts WW, Walsh PC, Platz EA. Family history of prostate cancer and obesity in relation to high-grade disease and extraprostatic extension in young men with prostate cancer. Prostate. 2003;55:140-146.
23. Friedman JM, Halaas JL. Leptin and the regulation of body weight in mammals. Nature. 1998;395:763-770.
24. Altman DG, Lausen B, Sauerbrei W, Schumacher M. Dangers of using "optimal" cutpoints in the evaluation of prognostic factors. J Natl Cancer Inst. 1994;86:829-835.
25. Simon R, Altman DG. Statistical aspects of prognostic factor studies in oncology. Br J Cancer. 1994;69:979-985.
26. D'Amico AV, Cote K, Loffredo M, Renshaw AA, Chen MH. Pretreatment predictors of time to cancer specific death after prostate specific antigen failure. J Urol. 2003;169:1320-1324.